Название: Nanopharmaceutical Advanced Delivery Systems
Автор: Группа авторов
Издательство: John Wiley & Sons Limited
Жанр: Программы
isbn: 9781119711681
isbn:
2 Chapter 2Table 2.1a Classification of nanoparticulate carrier systems.Table 2.1b Targeted treatment of tuberculosis using various nano-carrier-based d...Table 2.2 Schematic representation of classification of polymer based on their o...
3 Chapter 3Table 3.1 An overview of the nanotools.
4 Chapter 4Table 4.1 Properties of dendrimers.Table 4.2 Mechanism of bonding of various anticancer drugs with dendrimers.Table 4.3 Description of research on dendrimers.
5 Chapter 5Table 5.1 Composition, characterization, and application of recent nanofiber for...Table 5.2 Advantages of different biodegradable polymers used in the fabrication...
6 Chapter 6Table 6.1 Clinically approved microbubbles.Table 6.2 List of preclinical studies of brain tumor targeting by microbubbles.
7 Chapter 7Table 7.1 Various techniques used for characterisation of virosomes.
8 Chapter 8Table 8.1 Properties of commonly used polymers as nanocarriers.Table 8.2 Approved gene therapy products [45, 46].
9 Chapter 9Table 9.1 List of Phyto-phospholipid complexes fabricated by employing various p...Table 9.2 Marketed Phytosomal Preparations along with their indications.
10 Chapter 11Table 11.1 pH variations in several tissues and cellular regions.Table 11.2 Types of pH responsive polymers and their applications in drug delive...Table 11.3 List of temperature responsive polymeric nano-formulations.Table 11.4 The different stimuli-responsive polymeric systems and their drug rel...Table 11.5 List of dual and multi responsive polymeric systems.
11 Chapter 12Table 12.1 List of some drugs formulated as nanosomal formulations.
12 Chapter 14Table 14.1 Types of forces and their attributes in mucoadhesive systems.Table 14.2 Theories of mucoadhesion.Table 14.3 Classification of mucoadhesive polymers.Table 14.4 Influence of polymer properties on mucoadhesion.Table 14.5 Modified mucoadhesive polymers.
13 Chapter 15Table 15.1 Prevalence, Prognosis, and various alternative therapies [4, 5].
14 Chapter 16Table 16.1 List of nano-based vaginal formulations.Table 16.2 Patents on vaginal delivery.
15 Chapter 17Table 17.1 List of recently USFDA-approved drugs for the treatment of cancer.Table 17.2 List of liposomal drugs currently present in clinical trials for the ...Table 17.3 Liposomes functionalized with targeting ligands through surface engin...Table 17.4 Liposomes functionalized with stimuli for improved delivery of antica...Table 17.5 Recent drug polymeric nanocarriers used in drug delivery for treatmen...Table 17.6 Recent polymer modified liposomes for treatment of cancer.
16 Chapter 18Table 18.1 Dose of streptomycin, rifampicin and clarithromycin according to body...Table 18.2 Classification of severity of Chagas disease according to New York He...Table 18.3 Various chemotherapeutic agents used for various conditions in cystic...Table 18.4 Various agents used for various conditions in dengue fever.Table 18.5 Available medication for symptomatic relief in case of Dracunculosis.Table 18.6 Medication prescribed for treatment of Fascioliasis.Table 18.7 Medication according to parasitic infection and recommended dose for ...Table 18.8 Treatment for specific stages and parasite involved in Human African ...Table 18.9 Various drugs used in treatment of leishmaniasis and their route for ...Table 18.10 Various antibiotics for different type of leprosy in treatment of le...Table 18.11 Class of drug available for lymphatic filariasis with duration of th...Table 18.12 Drugs used for various organisms in case of Mycetoma treatment.Table 18.13 Drugs used for treatment of CBM.Table 18.14 Class of compounds used for treatment of other deep mycoses.Table 18.15 Available drugs for treatment of Onchocerciasis.Table 18.16 Treatment for Schistosomiasis along with dosage regimen in special g...Table 18.17 Therapeutics available for soil transmitted helminthiases [159].Table 18.18 Treatment available for Trachoma [112].Table 18.19 Antibiotics employed for treatment of Yaws.Table 18.20 Design and development of nanomedicines for neglected diseases.
17 Chapter 19Table 19.1 Regulatory approach in different reteams of world at a glance.
Guide
1 Cover
5 Preface
7 Index
Pages
1 v
2 ii
3 iii
4 iv
5 xxi
6 xxii
7 1
8 3
9 4
10 5
11 6
12 7
13 8
14 9
15 СКАЧАТЬ